Deferiprone
Clinical data | |
---|---|
Trade names | Ferriprox |
AHFS/Drugs.com | International Drug Names |
License data |
|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | V03AC02 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Glucuronidation |
Biological half-life | 2 to 3 hours |
Excretion | Renal (75 to 90% in 24 hours) |
Identifiers | |
| |
CAS Number | 30652-11-0 |
PubChem (CID) | 2972 |
IUPHAR/BPS | 7456 |
ChemSpider | 2866 |
UNII | 2BTY8KH53L |
KEGG | D07416 |
ChEBI | CHEBI:68554 |
ChEMBL | CHEMBL70927 |
ECHA InfoCard | 100.157.470 |
Chemical and physical data | |
Formula | C7H9NO2 |
Molar mass | 139.152 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major.[1] It was first approved for use in treating thalassaemia major in 1994[2] and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States.[1][3] On October 14, 2011, it was approved for use in the US under the FDA’s accelerated approval program.[4]
Controversy
Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America.[5] Dr. Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.[6][7]
See also
References
- 1 2 Savulescu J (2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851. Full Text.
- ↑ Staff, Cipla. Cipla's History
- ↑ http://www.docguide.com/dg.nsf/PrintPrint/F8BC7049D350C2AD852568A2006FEAAC
- ↑ FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
- ↑ Viens A, Savulescu J (2004). "Introduction to The Olivieri symposium.". J Med Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.
- ↑ Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D (2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90; author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794. Full Text.
- ↑ Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871. Full Text.